

## Invitation to SynAct Pharma's Capital Markets Day

**SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, invites investors, analysts and media to a Capital Markets Day on Monday, September 23, 10:00-13:00 CEST at GT30, Grev Turegatan 30 in Stockholm.**

The presentations will give an update on SynAct Pharma's strategy and offer an opportunity for participants to learn more about resomelagon's role in resolving inflammation through selective activation of the melanocortin system and the company's next clinical development of resomelagon with the Phase IIb clinical study ADVANCE in the US and Europe.

### Agenda

- 10:00 Introduction and corporate update – Jeppe Øvlesen, CEO
- 10:15 SynAct strategy and direction – Anders Kronborg, Chairman of the Board
- 10:25 Resolution therapy - Novel approach to the clinical management of inflammatory diseases – Prof. Mauro Perretti
- 10:45 Current and Future Treatments of Early Rheumatoid Arthritis and the Medical Need – Asger Reinstrup Bihlet, CSO at Sanos Group
- 11:05 Q&A session
- 11:25 *Break*
- 11:40 Resomelagon program and ADVANCE study – Thomas Jonassen, CSO
- 12:05 Emerging Clinical profile in newly-diagnosed RA patients - the business case – Jim Knight, CBO
- 12:30 Sector and market overview – Sten Scheibye, Member of the Board
- 12:40 Q&A session
- 12:55 Wrap-up and summary – Jeppe Øvlesen, CEO
- 13:00 Reception and lunch

**Location:** Grev Turegatan 30, 114 38 Stockholm

**Date:** Monday, September 23, 2024

**Time:** 10:00-13:00. The venue opens at 09:30.

The Capital Markets Day will be held in English. Presentation material will be available on SynAct's website afterwards.

Registration for the Capital Markets Day is made by emailing [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com).

The last day to register is September 19, 2024.

**For further information, please contact:**

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: + 45 2844 7567

E-mail: [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com)

**About SynAct Pharma AB**

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: [www.synactpharma.com](http://www.synactpharma.com).

**Attachments**

[Invitation to SynAct Pharma's Capital Markets Day](#)